S&P 500   3,849.62 (-0.15%)
DOW   30,937.04 (-0.07%)
QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
S&P 500   3,849.62 (-0.15%)
DOW   30,937.04 (-0.07%)
QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
S&P 500   3,849.62 (-0.15%)
DOW   30,937.04 (-0.07%)
QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
S&P 500   3,849.62 (-0.15%)
DOW   30,937.04 (-0.07%)
QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
Log in
NYSE:NVS

Novartis Stock Forecast, Price & News

$95.94
-2.53 (-2.57 %)
(As of 01/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$93.91
Now: $95.94
$95.94
50-Day Range
$88.18
MA: $92.96
$96.92
52-Week Range
$69.18
Now: $95.94
$99.84
Volume4.21 million shs
Average Volume2.10 million shs
Market Capitalization$219.58 billion
P/E Ratio31.05
Dividend Yield2.04%
Beta0.59
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Its Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, established, and cardiovascular, renal and metabolism medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has collaboration agreements with Pear Therapeutics; Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute; Science 37; Bill & Melinda Gates Foundation; Amgen; University of California, Berkeley; Bristol-Myers Squibb; Drugs for Neglected Diseases initiative (DNDi); TScan Therapeutics; Dyno Therapeutics Inc.; and Olema Oncology. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Novartis logo

MarketRank

Overall MarketRank

1.98 out of 5 stars

Medical Sector

63rd out of 1,925 stocks

Pharmaceutical Preparations Industry

25th out of 773 stocks

Analyst Opinion: 3.2Community Rank: 2.3Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone41-61-324-1111
Employees110,000
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$47.50 billion
Cash Flow$8.12 per share
Book Value$24.53 per share

Profitability

Net Income$11.73 billion

Miscellaneous

Outstanding Shares2,288,700,000
Market Cap$219.58 billion
Next Earnings Date1/26/2021 (Confirmed)
OptionableOptionable
$95.94
-2.53 (-2.57 %)
(As of 01/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novartis (NYSE:NVS) Frequently Asked Questions

How has Novartis' stock price been impacted by Coronavirus?

Novartis' stock was trading at $82.14 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVS shares have increased by 16.8% and is now trading at $95.94.
View which stocks have been most impacted by COVID-19
.

Is Novartis a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Novartis stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.
View analyst ratings for Novartis
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Novartis?

Wall Street analysts have given Novartis a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Novartis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Vas Narasimhan's approval rating as Novartis' CEO?

938 employees have rated Novartis CEO Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among Novartis' employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

When is Novartis' next earnings date?

Novartis is scheduled to release its next quarterly earnings announcement on Tuesday, January 26th 2021.
View our earnings forecast for Novartis
.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) announced its quarterly earnings results on Tuesday, January, 26th. The company reported $1.34 earnings per share for the quarter, missing the Zacks' consensus estimate of $1.37 by $0.03. The company earned $12.77 billion during the quarter, compared to the consensus estimate of $12.86 billion. Novartis had a net margin of 14.71% and a trailing twelve-month return on equity of 24.39%. The business's revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.32 earnings per share.
View Novartis' earnings history
.

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis declared an annual dividend on Monday, February 3rd. Investors of record on Wednesday, March 4th will be paid a dividend of $3.0425 per share on Thursday, March 12th. This represents a dividend yield of 2%. The ex-dividend date of this dividend is Tuesday, March 3rd. This is a positive change from Novartis's previous annual dividend of $2.86.
View Novartis' dividend history
.

Is Novartis a good dividend stock?

Novartis pays an annual dividend of $2.01 per share and currently has a dividend yield of 2.04%. The dividend payout ratio of Novartis is 38.36%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novartis will have a dividend payout ratio of 30.83% next year. This indicates that Novartis will be able to sustain or increase its dividend.
View Novartis' dividend history.

What price target have analysts set for NVS?

10 brokers have issued 12-month price targets for Novartis' stock. Their forecasts range from $112.00 to $116.00. On average, they anticipate Novartis' share price to reach $114.00 in the next year. This suggests a possible upside of 18.8% from the stock's current price.
View analysts' price targets for Novartis
or view Wall Street analyst' top-rated stocks.

Who are some of Novartis' key competitors?

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), The Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).

Who are Novartis' key executives?

Novartis' management team includes the following people:
  • Dr. Vasant Narasimhan, Chief Exec. Officer (Age 45)
  • Mr. Harry Kirsch, Chief Financial Officer (Age 56)
  • Mr. Steffen Lang Ph.D., Global Head of Technical Operations (Age 54)
  • Ms. Shannon Thyme Klinger, Chief Legal Officer (Age 50)
  • Dr. Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer (Age 53)
  • Mr. Steven Baert, Chief People & Organization Officer (Age 47)
  • Mr. Bertrand J.F.X. Bodson, Chief Digital Officer (Age 46)
  • Dr. John Tsai, Head of Global Drug Devel. & Chief Medical Officer (Age 54)
  • Mr. Robert Weltevreden, Head of Novartis Bus. Services (Age 52)
  • Ms. Susanne Schaffert Ph.D., Pres of Novartis Oncology (Age 54)

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Who are Novartis' major shareholders?

Novartis' stock is owned by many different retail and institutional investors. Top institutional investors include Manning & Napier Group LLC (0.09%), Schafer Cullen Capital Management Inc (0.09%), Scharf Investments LLC (0.05%), Douglas Lane & Associates LLC (0.03%), Cullen Capital Management LLC (0.02%) and Welch Group LLC (0.02%).

Which institutional investors are selling Novartis stock?

NVS stock was sold by a variety of institutional investors in the last quarter, including Schafer Cullen Capital Management Inc, Cullen Capital Management LLC, Manning & Napier Group LLC, Scharf Investments LLC, Transform Wealth LLC, Scout Investments Inc., Clark Capital Management Group Inc., and Grassi Investment Management.

Which institutional investors are buying Novartis stock?

NVS stock was purchased by a variety of institutional investors in the last quarter, including Kestra Advisory Services LLC, Douglas Lane & Associates LLC, Pacer Advisors Inc., TIAA FSB, Cardinal Capital Management Inc., Kestra Private Wealth Services LLC, FNY Investment Advisers LLC, and Altfest L J & Co. Inc..

How do I buy shares of Novartis?

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $95.94.

How big of a company is Novartis?

Novartis has a market capitalization of $219.58 billion and generates $47.50 billion in revenue each year. The company earns $11.73 billion in net income (profit) each year or $5.24 on an earnings per share basis. Novartis employs 110,000 workers across the globe.

What is Novartis' official website?

The official website for Novartis is www.novartis.com.

How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]

This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.